Frontiers in HIV ResearchVolume 1
Gene D. Morse, Sarah Nanzigudiseases associated with it. Although HIV has caused millions of deaths especially in Sub-Saharan
Africa, no fully reliable cure or prevention of the viral transmission has been identified. Drugs that
suppress viral replication (antiretrovirals) remain the only hope for millions of persons infected
with the virus. Since the approval of the first antiretroviral agent in 1985, over 30 such products
have been registered. Treatment regimens changed from single drug therapies to combinations
with highly active antiretroviral drugs, and those combinations also keep changing with new
information and therapies. Consolidated updates on data and evidence of effectiveness of these
drugs need to be availed to scientists and clinical practitioners. The ever increasing information
motivated the writing of a comprehensive book containing consolidated information on the
different available and upcoming antiretroviral agents. This book, edited by Prof. Gene Morse and
Dr. Sarah Nanzigu provides these materials with considerations of approaches by experts from
developed and developing settings. We highly appreciate these experts for their valued input.
This book with updated information on therapies used in HIV management is carefully relayed
under respective classes of drugs including Reverse Transcriptase Inhibitors (RTIs), Protease
Inhibitors (PI), Integrase Strand Inhibitors (INSTI), and Entry Inhibitors. Clinically relevant
information regarding activity of these agents in different populations is also presented, including
comparison of treatment options between resource-limited and resource-rich settings, together
with its implications. The book is carefully constructed to become a very valuable asset for
scientists and clinicians at different levels of understanding of these drugs. We will highly
appreciate feedback from our esteemed readers.